Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00092924 · ClinicalTrials.gov registry record · Phase 2
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00092924: Completed Phase 2 study, sponsored by Human Genome Sciences.
NCT00092924 is a Phase 2 study that has completed, run by Human Genome Sciences. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00092924, a Phase 2 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
Interventions
- DRUG TRAIL-R1 mAb (TRM-1;HGS-ETR1)
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
What the finished NCT00092924 record still lists
NCT00092924 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which TRAIL-R1 mAb (TRM-1;HGS-ETR1) is the first listed.
NCT00092924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00092924 about?
NCT00092924 is a clinical study titled "Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
What is the current status of trial NCT00092924?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00092924?
The interventions under investigation include: TRAIL-R1 mAb (TRM-1;HGS-ETR1) (DRUG).
Who is sponsoring clinical trial NCT00092924?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.